Takayama K, et al. - Among chemotherapy-naive patients (n = 140) with IIIB/IV non-small cell lung cancer (NSCLC) and a performance status of 0–1, researchers assessed the effectiveness of biweekly and weekly PC therapy (paclitaxel [P] plus carboplatin [C]), so that the appropriate chemotherapy schedule could be identified for Asian patients. Randomly, they allocated patients to a biweekly regimen (paclitaxel 135 mg/m² with carboplatin area under the curve [AUC] 3 on days 1 and 15 of every 4 weeks) or to a weekly regimen (paclitaxel 90 mg/m² on days 1, 8, and 15 with carboplatin AUC 6 on day 1 of every 4 weeks). Better objective response rate and progression-free survival were reported in the weekly regimen vs biweekly schedule, although a statistical difference was not found. Both regimens displayed a generally mild toxicity profile. In NSCLC treatment, the weekly PC regimen was appropriate as an alternative to the current 3-weekly regimen.